The noradrenergic symptom cluster: clinical expression and neuropharmacology. - Wikidata - wikimedia - TriplyDB

The noradrenergic symptom cluster: clinical expression and neuropharmacology.

The noradrenergic symptom cluster: clinical expression and neuropharmacology.

http://www.wikidata.org/entity/Q30474844

about

The noradrenergic paradox: implications in the management of depression and anxiety Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects Mutual independence of 5-HT(2) and α1 noradrenergic receptors in mediating deficits in sensorimotor gating.Arctigenin enhances swimming endurance of sedentary rats partially by regulation of antioxidant pathways.Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.The neuroimmune basis of fatigue The role of sleep in emotional brain function.The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone.Astroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis.

P2860

Q26752868-402E8F9C-D3ED-4192-976B-751D7E3A9D04 Q26799409-0130C229-4319-4F15-A764-3D72BE790BD4 Q30435174-59FC76F7-B12D-426C-95DE-BA2F5B72DFA7 Q34295032-7E44DB52-E134-4E2E-A99F-695F4B12AE0D Q34395091-38268712-6871-4D24-8E5C-16CC6557D961 Q37470201-1CCAF073-C796-4DC3-9074-856867CD04E4 Q38185423-659DFFD2-B44A-4155-9F48-DD1716306C4F Q47141387-C935FF67-957B-4A2A-BFCB-733B51915C09 Q47680320-22001AD8-5850-4F32-BC40-E5BCB03C3C34

P2860

The noradrenergic symptom cluster: clinical expression and neuropharmacology.

http://www.wikidata.org/entity/Q30474844

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

The noradrenergic symptom cluster: clinical expression and neuropharmacology.

@ast

The noradrenergic symptom cluster: clinical expression and neuropharmacology.

@en

type

label

The noradrenergic symptom cluster: clinical expression and neuropharmacology.

@ast

The noradrenergic symptom cluster: clinical expression and neuropharmacology.

@en

prefLabel

The noradrenergic symptom cluster: clinical expression and neuropharmacology.

@ast

The noradrenergic symptom cluster: clinical expression and neuropharmacology.

@en

P1433

Q30474844-B2E16CB0-456A-40F2-A174-1F245ECE9CF0

P1476

Q30474844-4B54F3DD-12DB-4B54-8EC8-8BA8E78F0C7C

P2093

Q30474844-49DABEAF-42CF-4415-B66C-0CE43EDE5C79

Q30474844-D5B59F7F-70D0-4FAF-998E-CAA609D7BD2B

P2860

Q30474844-0A04D832-D82A-4869-A68B-66570E5F5222

Q30474844-0A1CB3D0-336E-47DB-88B8-70D01D047A5F

Q30474844-133AA0D1-B001-4253-9C9C-F0107D8BD7AB

Q30474844-2355A5DD-C59A-4F93-859F-3A2169DFDEDB

Q30474844-2EFEEB31-74B0-4116-BCD8-ACA6F54C03DD

Q30474844-340E7A3C-CA84-4AFF-8504-13309D30FB7D

Q30474844-3F17ED25-27B1-4CA7-BE86-7A624E38154D

Q30474844-4A283822-082D-4C54-8891-6A5DEDB294AA

Q30474844-4FB8BD2F-93DE-4160-A38A-AA8563437716

Q30474844-6B1B439B-C228-4850-8DCA-FECFC3C5F6A1

P304

Q30474844-033848D6-7C4C-4463-A6B4-F2985B11E465

P31

Q30474844-A6FD0EDF-868F-4134-A025-06E56A8021C9

P356

Q30474844-7AA4B38C-ABC9-4FF3-877D-FD7C668F55CA

P407

Q30474844-B53AC12C-BBB0-4043-B9F1-832064B01762

P433

Q30474844-E3CA4A3B-0BA2-4799-ABED-C430DAC999D0

P478

Q30474844-02DA7DD0-B98D-4363-AEDD-F73C1AC36396

P577

Q30474844-E01C1F30-0D2B-4665-B31F-4DC5010561F1

P5875

Q30474844-D60C36BD-7BDE-4C1F-A50F-DAD43E3C4A49

P698

Q30474844-E910415B-1782-449B-A1A3-8DB19D3C1654

P932

Q30474844-1FD3FAFE-9C08-426C-B2F5-FBB414DAA3C5

P356

P1433

Neuropsychiatric Disease and Treatment

P1476

The noradrenergic symptom cluster: clinical expression and neuropharmacology.

@en

P2093

Mike Briley

http://www.w3.org/2001/XMLSchema#string

Pierre Blier

http://www.w3.org/2001/XMLSchema#string

P2860

The other face of depression, reduced positive affect: the role of catecholamines in causation and cure

Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug

SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.

Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions.

Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders.

Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression.

Molecular mechanisms of stress-induced prefrontal cortical impairment: implications for mental illness.

Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms.

The brainstem noradrenergic systems in stress, anxiety and depression.

P304

15-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/NDT.S19613

http://www.w3.org/2001/XMLSchema#string

P407

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51487096

http://www.w3.org/2001/XMLSchema#string

P698

21750624

http://www.w3.org/2001/XMLSchema#string

P932

3131097

http://www.w3.org/2001/XMLSchema#string